A Study to Investigate the Potential for AZD5672 to Affect the Electrical Conduction Pathways in the Heart

• Status: Completed
• Trial end date: 2009-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is being performed to investigate the potential for AZD5672 to affect the electrical conduction pathways in the heart. AZD5672 will be compared against a drug (moxifloxacin - a licensed antibiotic) known to have a detectable but safe change on the electrical conduction of the heart.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Collaborator: Quintiles, Inc.
• Treatments: Fluoroquinolones; Moxifloxacin; N-(1-(3-(3,5-difluorophenyl)-3-(4-methanesulfonylphenyl)propyl)piperidin-4-yl)-N-ethyl-2-(4-methanesulfonylphenyl)acetamide; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Body Mass Index (BMI) between 18 and 30 kg/m2 and a minimum weight of 50kg.

• Non-smoker

Exclusion Criteria:

• Marked QTc prolongation at baseline e.g. repeated demonstration of QTc interval >450ms or marked shortening of QTcF <350ms

• Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of the QTc Interval changes

• Use of concomitant medications that prolong QT/QTc interval